Skip to content
RDL Network logo
Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study — Meletios A Dimopoulos (2015) | RDL Network